These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
275 related items for PubMed ID: 21577323
21. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE. Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022 [Abstract] [Full Text] [Related]
25. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. J Clin Oncol; 2010 Jun 01; 28(16):2739-47. PubMed ID: 20439648 [Abstract] [Full Text] [Related]
28. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. Am J Hematol; 2014 Nov 01; 89(11):E193-9. PubMed ID: 25042343 [Abstract] [Full Text] [Related]
30. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype]. Su L, Li W, Cui JW, Tan YH, Yang Y, Liu XL, Yu P, Hu RP, Wang LL, Gao SJ. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 01; 21(3):571-5. PubMed ID: 23815900 [Abstract] [Full Text] [Related]
31. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Cancer; 2012 Jun 01; 118(11):2879-88. PubMed ID: 22038701 [Abstract] [Full Text] [Related]